Dupilumab - Regeneron/Sanofi

Drug Profile

Dupilumab - Regeneron/Sanofi

Alternative Names: Dupilumab - Sanofi/Regeneron; Dupixent; REGN 668; SAR 231893

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor type I antagonists; Interleukin 4 receptor type II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase III Asthma; Nasal polyps
  • Phase II Eosinophilic oesophagitis
  • Phase I Allergic asthma

Most Recent Events

  • 16 Oct 2017 Dupilumab - Regeneron/Sanofi receives Orphan Drug status for Eosinophilic oesophagitis in USA
  • 16 Oct 2017 Positive efficacy and safety data from a phase II trial in Eosinophilic oesophagitis released by Sanofi and Regeneron Pharmaceuticals
  • 28 Sep 2017 Registered for Atopic dermatitis (Adjunctive treatment, In adults) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top